Table 3 Antifungal therapy started before and after microbiological documentation of Candida in the bloodstream

Antifungal therapy administered before microbiological documentation

22 (34.9%)

47 (56.0%)

0.011

 Treatment method

  Prophylactic treatment

7 (11.1%)

17 (20.2%)

0.138

  Empiric treatment

12 (19.0%)

23 (27.4%)

0.240

  Undetermined^a

3 (4.8%)

7 (8.3%)

0.603

 Agents selection

  Fluconazole

16 (25.4%)

32 (38.1%)

0.104

  Itraconazole

3 (4.8%)

11 (13.1%)

0.089

  Voriconazole^a

3 (4.8%)

4 (4.8%)

0.696

Antifungal therapy administered/changed after microbiological documentation

28 (44.4%)

36 (42.9%)

0.848

 Agents selection

  Fluconazole

4 (6.3%)

13 (15.5%)

0.087

  Itraconazole^a

6 (9.5%)

3 (3.6%)

0.253

  Voriconazole^a

4 (6.3%)

6 (7.1%)

0.887

  Micafungin^a

3 (4.8%)

5 (6.0%)

0.958

  Caspofungin

11 (17.5%)

9 (10.7%)

0.238

Overall

 Triazoles usage

36 (57.1%)

66 (78.6%)

0.005

 Echinocandins usage

14 (22.2%)

14 (16.7%)

0.396

 Absence of antifungal therapies

16 (25.4%)

10 (11.9%)

0.034